TY - JOUR
AU1 - Pagano, Paul J.
AU2 - Chong, Kong-Teck
AB - Delavirdine (bisheteroarylpiperazine, U-90152), a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), was evaluated in a two-drug combination with recombinant human interferon-a (IFN-α) or the peptidomimetic protease inhibitor U-75875 against HIV-l replication in vitro. Viral growth was assayed in a CD4+ T cell line (H9) infected with HIVIIIB and in human peripheral blood mononuclear cells infected with the clinical isolate HIVJRCSF . Drug synergy, estimated by the combination index method and the method of Pritchard and Shipman, was observed when delavirdine was combined with U-75875 or IFN-α over a range of drug concentrations (delavirdine: 0.001, 0.003, 0.01, 0.03 µM ; U-75875: 0.01, 0.03,0.1,0.3, 1.0 µM ; IFN-α: 2,6, 17, and 50 or 10,30, 100, and 300 IU/mL). The combinations showed no detectable drug antagonism or cytotoxicity. These in vitro synergy data support the potential use of delavirdine with either a protease inhibitor or IFN-α in patients with AIDS.
TI - In Vitro Inhibition Of Human Immunodeficiency Virus Type 1 By A Combination Of Delavirdine (U-90152) With Protease Inhibitor U-75875 Or Interferon-α
JF - The Journal of Infectious Diseases
DO - 10.1093/infdis/171.1.61
DA - 1995-01-01
UR - https://www.deepdyve.com/lp/oxford-university-press/in-vitro-inhibition-of-human-immunodeficiency-virus-type-1-by-a-N3Fjersepm
SP - 61
EP - 67
VL - 171
IS - 1
DP - DeepDyve
ER -